State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma.
Diffuse large B-cell lymphoma (DLBCL) represents the most common lymphoid malignancy in adults, with a median age of 60 to 70 years. Clinical behavior is usually rapidly aggressive, with extranodal involvement in 40% of cases. Chemoimmunotherapy administered every 21 days is still the standard of care in the advanced stage. Optimization of frontline therapy and the amelioration of salvage strategies remain the most important targets in the treatment of patients with DLBCL. Novel drugs directed to specific molecular targets have been introduced as single agents or in addition to standard chemoimmunotherapy for the treatment of DLBCL.